Literature DB >> 19639168

Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis.

Mitsuro Kanda1, Shuji Nomoto, Yukiyasu Okamura, Yoko Nishikawa, Hiroyuki Sugimoto, Naohito Kanazumi, Shin Takeda, Akimasa Nakao.   

Abstract

Gene expression profiling or karyotyping analysis has made it possible to identify novel genes with altered expressions or copy numbers that have not been previously reported in liver cancer. On the same HCC sample, we performed double array analysis, both expression profiling and karyotyping analysis using a single nucleotide polymorphism (SNP) array in an attempt to find a novel tumor suppressor gene for its prognostic marker. We conducted expression array and SNP chip array using tumor and corresponding non-tumor tissues from the resected liver specimen of a 68-year-old woman who had chronic hepatitis type C. Additionally, we performed quantitative real-time reverse transcription polymerase chain reaction (PCR) and methylation-specific PCR (MSP) for gene detection using specimens from 48 patients with HCC, and investigated their correlation with the prognosis. Metallothionein (MT) 1G gene located on 16q13 showed a decreased expression in tumor tissue. The copy number by SNP chip array revealed no loss of heterozygosity since no deletions were detected in 16q13, and HCC tissue showed AB call in both SNPs next to MT1G. In quantitative real-time PCR using 48 HCC clinical samples, mRNA expression of MT1G decreased significantly compared with that in corresponding non-cancerous liver tissues (p<0.0323). Twenty-nine (60.4%) of 48 HCCs gave a positive result in MSP, indicating a poorer prognosis than the negative group, although the difference was not significant (p<0.0978). Our results indicated that MT1G acts as a tumor suppressor gene in HCC. Moreover, findings suggested that the mechanisms of MT1G silencing are related to promoter hypermethylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639168     DOI: 10.3892/ijo_00000359

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  47 in total

1.  Gene expression and pathway analysis of human hepatocellular carcinoma cells treated with cadmium.

Authors:  Laura Cartularo; Freda Laulicht; Hong Sun; Thomas Kluz; Jonathan H Freedman; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2015-08-24       Impact factor: 4.219

2.  Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population.

Authors:  Katarzyna Starska; Anna Krześlak; Ewa Forma; Jurek Olszewski; Iwona Lewy-Trenda; Ewa Osuch-Wójcikiewicz; Magdalena Bryś
Journal:  Med Oncol       Date:  2014-06-22       Impact factor: 3.064

3.  Prognostic relevance of SAMSN1 expression in gastric cancer.

Authors:  Mitsuro Kanda; Dai Shimizu; Satoshi Sueoka; Shuji Nomoto; Hisaharu Oya; Hideki Takami; Kazuhiro Ezaka; Ryoji Hashimoto; Yuri Tanaka; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2016-10-06       Impact factor: 2.967

4.  Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.

Authors:  Xiaofang Sun; Xiaohua Niu; Ruochan Chen; Wenyin He; De Chen; Rui Kang; Daolin Tang
Journal:  Hepatology       Date:  2016-05-24       Impact factor: 17.425

5.  Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis.

Authors:  Daisuke Kobayashi; Shuji Nomoto; Yasuhiro Kodera; Michitaka Fujiwara; Masahiko Koike; Goro Nakayama; Norifumi Ohashi; Akimasa Nakao
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

6.  MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma.

Authors:  Xiang-Fen Ji; Yu-Chen Fan; Shuai Gao; Yang Yang; Jian-Jun Zhang; Kai Wang
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

7.  Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer.

Authors:  Mitsuro Kanda; Hisaharu Oya; Shuji Nomoto; Hideki Takami; Dai Shimizu; Ryoji Hashimoto; Satoshi Sueoka; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

8.  Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry.

Authors:  Yiyi Sun; Zhihe Zang; Xiaohong Xu; Zhonglin Zhang; Ling Zhong; Wang Zan; Yan Zhao; Lin Sun
Journal:  Int J Mol Sci       Date:  2010-03-31       Impact factor: 5.923

9.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

10.  NRAGE promotes the malignant phenotype of hepatocellular carcinoma.

Authors:  Dai Shimizu; Mitsuro Kanda; Hiroyuki Sugimoto; Satoshi Sueoka; Hideki Takami; Kazuhiro Ezaka; Yuri Tanaka; Ryoji Hashimoto; Yukiyasu Okamura; Naoki Iwata; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Masahiko Koike; Shuji Nomoto; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.